Table 2.

Change in cell marker expression following treatment in the responder and non-responder groups

			Week 0	Week 12	P-value
CD3	etanercept	R n = 12	27.5 (6.5 to 1121)	16 (0.5 to 113)	0.05*
		NR n = 1	17	14	n/a
	anakinra	R n = 4	33.5 (1 to 1344)	32.9 (3 to 734)	0.47
		NR n = 4	87.9 (13 to 265)	300 (166 to 389)	0.068
CD68sl	etanercept	R n = 12	127 (138 to 3,543)	712 (112 to 2,318)	0.31
		NR n = 1	1,408	1,667	n/a
	anakinra	R n = 4	1,370 (362 to 2,685)	1,444 (453 to 2,414)	0.72
		NR n = 4	1,431 (494 to 1,795)	1,879 (1,741 to 2,218)	0.068
CD68ll	etanercept	R n = 12	226 (38 to 513)	213 (17 to 466)	0.48
		NR n = 1	191	150	n/a
	anakinra	R n = 4	174 (129 to 469)	214 (154 to 473)	0.47
		NR n = 4	159 (108 to 197)	147 (104 to 319)	0.72
FVlll	etanercept	R n = 11	132,242 (43,272 to 754,550)	139,294 (51,817 to 439,712)	0.53
		NR n = 1	58,525	142,834	n/a
	anakinra	R n = 4	218,619 (88,372 to 353,725)	280,785 (226,415 to 353,725)	0.27
		NR n = 4	286,939 (84,419 to 521,103)	437,447 (184,155 to 545,675)	0.72
MRI	etanercept	R n = 13	8 (4 to 12)	5 (2 to 11)	0.12
		NR n = 1	3	1	n/a
	anakinra	R n = 5	4 (4 to 12)	4 (4 to 9)	0.66
		NR n = 3	4 (0 to 11)	4 (4 to 7)	1

Median (range). n/a, not applicable; NR, non-responder; R, responder